Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - A hostile bid by the world's largest drug maker Pfizer to thwart a deal for a majority stake by Japan's Daiichi Sankyo in India's top generic firm Ranbaxy Laboratories would likely be rebuffed by management led by the Singh family, which holds nearly 35 percent of the firm, analysts said

You may also be interested in...



Ranbaxy and Pfizer Settle Lipitor Litigation

MUMBAI - Ranbaxy Laboratories said on June 18 that it has settled most of the patent litigations involving Lipitor (atorvastatin) with Pfizer, putting an end to a five-year legal battle between the two companies

Ranbaxy and Pfizer Settle Lipitor Litigation

MUMBAI - Ranbaxy Laboratories said on June 18 that it has settled most of the patent litigations involving Lipitor (atorvastatin) with Pfizer, putting an end to a five-year legal battle between the two companies

Analysts See Daiichi Sankyo Exercising Light Control Of Ranbaxy

NEW DELHI - Japan's Daiichi Sankyo will let the current management of India's top drug firm Ranbaxy Laboratories have a free hand in pursuing new ties-ups and expanding generic sales globally following the model set by Novartis-Sandoz, analysts say

Related Content

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel